Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
COP$139.40+2.46(+1.80%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$636.83+6.83(+1.08%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$138.25+3.99(+2.97%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$352.33+2.82(+0.81%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETMU$762.31-33.15(-4.17%)Could Buying Micron Stock Today Help Set You Up for Life?7:17:00 AM ETMSFT$555.46-0.34(-0.06%)Microsoft Is Executing an Irreproducible Balance-Sheet-Backed Infrastructure Pre-Sale at Scale7:15:58 AM ETAAPL$352.33+2.82(+0.81%)Apple Vs. Tesla: Low CapEx Only Matters if Non-Cyclical Cash Flows Come With It7:15:57 AM ETIREN$20.93-0.77(-3.55%)IREN is Only Fit for a Specific Investor Currently7:15:22 AM ETCOP$139.40+2.46(+1.80%)BRIEF-Conocophillips Q3 Adjusted EPS USD 3.27 Vs. IBES Estimate USD 2.977:13:20 AM ETMU$762.31-33.15(-4.17%)Micron Just Closed Below $800 for the First Time Since July7:12:48 AM ETCOP$139.40+2.46(+1.80%)ConocoPhillips beats profit estimates, boosts quarterly dividend7:11:13 AM ETCRWD$233.65-7.35(-3.05%)Too Late to Buy CrowdStrike Stock? Here's the 1 Thing to Watch.7:10:00 AM ETGOOG$290.80+3.50(+1.22%)These 6 Stocks Make Up a Big Share of the S&P 5007:09:00 AM ETCOP$139.40+2.46(+1.80%)UPDATE 1-ConocoPhillips beats profit estimates, boosts quarterly dividend7:07:07 AM ETLLY$1,430.00+11.86(+0.84%)Iconic California Brand, French Florist, Celebrates Grand Opening of First Indiana Location7:07:00 AM ETCVS$81.00+1.01(+1.26%)ProjectLeo, the First Private AI Health Platform to Declare Independence From Big Tech7:04:00 AM ETCOP$139.40+2.46(+1.80%)ConocoPhillips beats quarterly profit estimates7:01:40 AM ETCOP$139.40+2.46(+1.80%)ConocoPhillips announces third-quarter 2026 results and increases quarterly ordinary dividend by 11%7:00:05 AM ETPG$168.66+1.34(+0.80%)P&G to Webcast Presentation From P&G Investor Day 2026, November 197:00:03 AM ETV$440.17+3.58(+0.82%)Visa Forecasts U.S. Holiday Spending to Rise 4.5% as Consumers Keep the Holidays a Priority7:00:00 AM ETHD$360.19+4.75(+1.34%)Transom Appoints David Shields as Executive Vice President, Operations and Finance7:00:00 AM ETGS$937.89+9.61(+1.04%)RPT-BREAKINGVIEWS-Hong Kong summit exposes Wall Street AI confusion7:00:00 AM ETDTE$138.25+3.99(+2.97%)DTE Energy to sell DTE Vantage business for about $3 billion6:59:28 AM ETACN$268.00+3.73(+1.41%)Mondelēz International and Accenture Transform Order-to-Cash With AI6:59:02 AM ET

AKBA · NASDAQ

Akebia Therapeutics, Inc.

$0.52 -0.17 (-24.64%)

Company overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$144M
Employees
181
Headquarters
Cambridge, MA
Website
akebia.com
CEO
John Butler
Listed
March 20, 2014
P/E
-6.61
Dividend yield
0.00%

Company financials

Revenue
$232M
Gross profit
$188M
Operating income
$5.3M
EBITDA
$3.2M
Net income
-$20.5M
EPS
-$0.08
Total assets
$363M
Total debt
$12.5M
Gross margin
80.87%
Net margin
-8.83%
Earnings yield
-15.12%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

0.500.771.041.311.58
AKBA 1D NASDAQ O0.75H0.75L0.66C0.69-0.04 (-5.24%)Vol10.55M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston GlobeNewswire
WDC Stock news Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Benzinga
AKBAAkebia Therapeutics, Inc. Stock news Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript Seeking Alpha
AKBAAkebia Therapeutics, Inc. Stock news Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates Zacks Investment Research
AKBAAkebia Therapeutics, Inc. Stock news Akebia Therapeutics Q2 Earnings Call Highlights MarketBeat
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases GlobeNewswire
AKBAAkebia Therapeutics, Inc. Stock news Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near MarketBeat
AKBAAkebia Therapeutics, Inc. Stock news Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript Seeking Alpha
AKBAAkebia Therapeutics, Inc. Stock news Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates Zacks Investment Research
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights GlobeNewswire
AKBAAkebia Therapeutics, Inc. Press release Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
See more
FAQ

Questions about Akebia Therapeutics, Inc.

What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd.
What is AKBA's market cap?
Akebia Therapeutics, Inc. (AKBA) is a listed stock with a live quote. The latest market cap on this page is $144M.
Where is Akebia Therapeutics, Inc. headquartered?
Akebia Therapeutics, Inc. is headquartered in Cambridge, MA.
How do I get AKBA news from the API?
Call GET /v1/news?tickers=AKBA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does AKBA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AKBA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the AKBA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs